Abstract Announcements and Exceptions
According to ASCO's Abstract Policy, abstracts submitted to the 2013 ASCO Annual Meeting, Gastrointestinal (GI) Cancers Symposium and Genitourinary (GU) Cancers Symposium are confidential from the time of submission until the specified embargo lift date and time when the data becomes publicly available. Under extenuating circumstances, ASCO may grant a formal exception to its Abstract Policy. Abstract Policy Exceptions require advance approval by ASCO before the information is made public.
ASCO has granted formal Policy Exceptions for the following abstracts to allow limited information to be made publicly available in advance of the 2014 Gastrointestinal Cancers Symposium:
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).
ASCO has granted formal Policy Exceptions for the following abstracts to allow limited information to be made publicly available in advance of the 2014 Genitourinary Cancers Symposium:
Enzalutamide in Men with Chemotherapy-naïve Metastatic Prostate Cancer (mCRPC): Results of Phase 3 PREVAIL Study
View the Abstract